Home / Investors / Patents

Patents and trademarks

PEPTONIC medical has secured a strong patent protection for Vagitocin® with coverage through 2032. The work with VagiVital® is ongoing.

Key claims include but are not limited to:

  • Use of Substances with Oxytocin Activity for Climateric/Menopausal Disorders.
  • Use of Oxytocin for the Preparation of a Pharmaceutical Composition Against Cancer in Situ and Cervictis, only in USA.
  • Novel Topical Composition of Oxytocin for use for Local Treatment of Vaginal Atrophy.
  • A peptide to create Eustasis, only in USA.

Patent strategy – Future possibilities

The company have filed a patent for the use of VagiVital® in climacteric disorders, it is still pending. Two other filed patents are pending, they cover oxytocin use in other indications. The intention are to file other additional patents in the area.

Trademarks

Vagitocin® is a proprietary trademark of PEPTONIC medical and is registered in Europe, USA and Australia. VagiVital® is also a proprietary trademark of PEPTONIC medical, at the moment approved throughout EU and in Norway. Work with extension of the countries is ongoing

 

Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.